Form 4: BioXcel Therapeutics Director Rajiv Patni Granted Stock Options

Rajiv Patni, a director at BioXcel Therapeutics, was granted options to purchase 44,000 shares of common stock on January 15, 2025.

Summary

• Rajiv Patni, a director of BioXcel Therapeutics, was granted stock options on January 15, 2025.
• The options allow him to purchase 44,000 shares of common stock at an exercise price of $0.3465 per share.
• The options vest in three equal installments on the first three anniversaries of the grant date, contingent on his continued service as a director.
• The options expire on January 15, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the options is dependent on the future performance of BioXcel Therapeutics' stock price.
• If the director leaves the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The director's stock options will vest over the next three years, contingent on continued service.

Industry Context

Granting stock options to directors is a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of three years is also typical, designed to retain talent and align long-term interests.
• The exercise price is set at a specific value, which is common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and performance.

Key Dates

Keywords

stock options, BioXcel Therapeutics, director, Rajiv Patni, equity compensation, vesting